Key points from article :
Proteolysis-targeting chimaeras (PROTACs) entering clinical trials this year.
Targeted protein degradation uses the cell’s natural system for clearing damaged proteins.
They destroy rather than inhibit proteins.
Can target proteins that drug developers have long considered undruggable.
Arvinas is scheduled to begin testing a PROTAC for prostate cancer.
PROTACs are molecules made up of two binding ends connected by a thin tether.
One end grabs on to the target protein.
Other end latches on to a ubiquitin ligase - part of the cell’s natural rubbish-disposal system.
Proximity is enough to ensure that the target will get marked for destruction.
